Best CDMOs in Switzerland — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform
14
CDMOs in region
8
Fully scored
6
With FDA records
27
FDA inspections
92
EMA/MHRA GMP certs

CDMO Signal tracks 14 biopharma CDMOs with confirmed Switzerland manufacturing facilities, of which 8 are fully scored across the four-pillar composite Signal Score. Across all modalities, Novartis, Bachem, and Takeda lead the Switzerland ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within Switzerland — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.

Swiss-based CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed Swiss facilities. Switzerland operates outside the EU but maintains regulatory alignment with EMA on GMP through mutual recognition, and hosts several of the world's largest CDMOs (Lonza, Bachem, CordenPharma). Swiss CDMOs typically hold Swissmedic, EMA, MHRA, and FDA certifications concurrently — Swiss manufacturing is designed for global supply. This ranking includes any CDMO with a Swiss manufacturing site.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
Novartis
Basel, Switzerland
88.3 90.9 16 insp · 65 GMP 135 programs
2
BA
Bachem
Bubendorf, CH
83.5 98.9 3 insp · 0 GMP 0 programs
3
TK
Takeda
Boston, MA · Zurich, CH
80.5 99.3 4 insp · 18 GMP 100 programs
4
NV
Novartis Contract Manufacturing
Morris Plains, NJ · Stein, CH
79.1 90.9 1 insp · 0 GMP Constrained 284 programs
5
Lonza
Basel, Switzerland
78.2 95.1 2 insp · 8 GMP 1 programs
6
CE
Celonic
Basel, Switzerland
78.1 100.0 0 insp · 1 GMP 0 programs
7
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
72.8 95.1 1 insp · 0 GMP Limited 0 programs
8
DINAMIQS
Schlieren (Zurich), Switzerland
59.0 Available 0 programs
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
Profiled 0 programs
Tecan Group / Tecan CDMO Solutions
Männedorf, Switzerland
Profiled 0 programs
NegotiumBio LLC & GmbH
Basel, Switzerland (GmbH) / US entity (LLC)
Profiled 0 programs
AliveDx
Eysins, Switzerland
Profiled 0 programs
Cerbios-Pharma
Lugano, Switzerland
Profiled 0 programs
Jetpharma SA
Balerna, Switzerland
Profiled 0 programs
How we score CDMOs →

Why are Swiss CDMOs positioned as premium-tier for biopharma manufacturing?

The Swiss CDMO cluster (Basel, Visp, Bern) hosts three attributes that reinforce a premium tier positioning: (1) regulatory alignment — Switzerland's Swissmedic runs a mutual-recognition GMP framework with the EU, so a Swiss facility supplying the EU doesn't need parallel EMA certification for the same activities; (2) technical depth — Swiss CDMOs have historically led on complex chemistry (Lonza on biologics + peptides, Bachem on peptides, CordenPharma on APIs) and on early-adopter viral vector manufacturing; (3) capital access — Swiss operations are able to make sustained capex investments in single-site scale-ups that lower-cost jurisdictions cannot match. That said, Swiss CDMOs also carry higher per-batch costs than Asian or Eastern European alternatives — the trade-off is process depth and regulatory posture, not price.

How does Switzerland's non-EU status affect drug supply to EU markets?

Switzerland is not an EU member state but maintains a bilateral Mutual Recognition Agreement (MRA) with the EU covering GMP inspections. Practically: a Swissmedic GMP inspection is recognized by EMA as equivalent to an EMA GMP inspection for the covered activity. Swiss-manufactured product does still require an EU-based Qualified Person for batch release into the EU market, but the facility itself does not need parallel EMA certification. This makes Swiss CDMOs operationally cleaner for pan-European supply than most non-EU alternatives. For UK supply, post-Brexit MHRA has continued to recognize the Swissmedic MRA under transitional arrangements — sponsors supplying both EU and UK should confirm current MHRA policy at RFP stage.

Which Swiss CDMOs are also present in the US and Asia?

The largest Swiss CDMOs — Lonza, CordenPharma, Bachem — operate global site networks spanning Switzerland, US, and (in Lonza's case) multiple Asian geographies. This multi-region posture materially reduces regulatory tech-transfer risk for programs supplying multiple markets from a single CDMO relationship. Cross-check with the US region ranking and Asia region ranking to identify Swiss-headquartered CDMOs with cross-jurisdictional footprint. Individual profile pages surface the specific site network.

Browse by modality within Switzerland

Modality-specific rankings for Switzerland-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed Switzerland facilities.

AAV / Gene Therapy (6) CAR-T (2) Lentiviral Vector (3) Cell Therapy (5) mRNA / LNP (3) Biologics / mAb (3) Oligonucleotide / ASO (3) Recombinant Proteins (2) ADC (Antibody-Drug Conjugate) (3) Gene Therapy (8) Cell & Gene Therapy (8) Viral Vector (6)
Other regions
CDMOs in United States CDMOs in Europe CDMOs in Asia CDMOs in United Kingdom CDMOs in India CDMOs in Germany CDMOs in South Korea CDMOs in Japan CDMOs in China